NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. More Details
Fair value with moderate growth potential.
Share Price & News
How has NuVasive's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NUVA is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: NUVA's weekly volatility (3%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: NUVA underperformed the US Medical Equipment industry which returned 30.8% over the past year.
Return vs Market: NUVA underperformed the US Market which returned 37.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is NuVasive's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StDoes NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?
3 weeks ago | Simply Wall StWho Has Been Buying NuVasive, Inc. (NASDAQ:NUVA) Shares?
1 month ago | Simply Wall StAre Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?
Is NuVasive undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NUVA ($65.4) is trading below our estimate of fair value ($88.19)
Significantly Below Fair Value: NUVA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NUVA is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: NUVA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NUVA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NUVA is good value based on its PB Ratio (4x) compared to the US Medical Equipment industry average (4.5x).
How is NuVasive forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NUVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: NUVA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NUVA's is expected to become profitable in the next 3 years.
Revenue vs Market: NUVA's revenue (6.8% per year) is forecast to grow slower than the US market (9.2% per year).
High Growth Revenue: NUVA's revenue (6.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NUVA's Return on Equity is forecast to be low in 3 years time (14.3%).
How has NuVasive performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NUVA is currently unprofitable.
Growing Profit Margin: NUVA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NUVA is unprofitable, and losses have increased over the past 5 years at a rate of 27.9% per year.
Accelerating Growth: Unable to compare NUVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NUVA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15.5%).
Return on Equity
High ROE: NUVA has a negative Return on Equity (-5.98%), as it is currently unprofitable.
How is NuVasive's financial position?
Financial Position Analysis
Short Term Liabilities: NUVA's short term assets ($781.6M) exceed its short term liabilities ($224.9M).
Long Term Liabilities: NUVA's short term assets ($781.6M) do not cover its long term liabilities ($1.1B).
Debt to Equity History and Analysis
Debt Level: NUVA's debt to equity ratio (105.3%) is considered high.
Reducing Debt: NUVA's debt to equity ratio has increased from 102.6% to 105.3% over the past 5 years.
Debt Coverage: NUVA's debt is well covered by operating cash flow (24.1%).
Interest Coverage: NUVA's interest payments on its debt are not well covered by EBIT (0.6x coverage).
What is NuVasive current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NUVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NUVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NUVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NUVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NUVA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Barry (48 yo)
Mr. J. Christopher Barry, also known as Chris, serves as Chief Executive Officer and Director of NuVasive, Inc., since November 5, 218. Mr. Barry served commercial and leadership roles at Covidien. He has ...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD4.82M) is about average for companies of similar size in the US market ($USD5.31M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
Experienced Management: NUVA's management team is considered experienced (2.6 years average tenure).
Experienced Board: NUVA's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
NuVasive, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: NuVasive, Inc.
- Ticker: NUVA
- Exchange: NasdaqGS
- Founded: 1997
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$3.381b
- Shares outstanding: 51.65m
- Website: https://www.nuvasive.com
Number of Employees
- NuVasive, Inc.
- 7475 Lusk Boulevard
- San Diego
- United States
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. it provides surgical access instruments, including Maxcess integrated split-blade ret...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/28 22:43|
|End of Day Share Price||2021/07/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.